Navigation Links
Compound used to block cholesterol could also kill breast cancer, MU researcher finds
Date:2/22/2011

COLUMBIA, Mo. A University of Missouri researcher believes there could be a new drug compound that could kill breast cancer cells. The compound might also help with controlling cholesterol.

Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center, and his research team discovered that a small molecule, Ro 48-8071, initially developed for controlling cholesterol synthesis "dramatically destroys" human breast cancer cells. This development was discovered as Hyder's research team was investigating PRIMA-1, a drug that targets a common mutated gene in human breast cancer cells, and kills tumor cells.

During the course of the study, Xiaoquin Zou, an assistant professor in the MU Department of Physics and Astronomy, compared the chemistry of PRIMA-1 binding to thousands of proteins using a software program she developed called MDock. Hyder and Zou found that PRIMA-1 showed excellent binding properties to a protein called oxidosqualene cyclase, (OSC) that is known to be important for producing cholesterol. This led Hyder's team to investigate whether known OSC inhibitors, such as Ro 48-8071, developed to stop cholesterol production, also killed breast cancer cells.

"We had been working with PRIMA-1 for some time, and what we didn't quite understand is exactly how it killed tumor cells," Hyder said. "With the current findings, we think it's possible that one mechanism utilized by PRIMA-1 to kill cancer cells may include shutting down cholesterol synthesis, but we still don't know for certain if that's the case. What we do know is that Ro 48-8071 does stop cholesterol synthesis, and it proved to be just as effective in destroying cancer cells as PRIMA-1, without harming other normal breast cells, which is a big advantage."

While there are still many studies to complete, including testing on humans, Hyder believes there are great possibilities in using Ro 48-8071 as a treatment for breast cancer. Hyder gives equal credit to MU colleagues Xiaoqin Zou, Sam Grinter, graduate student in physics; Yayun Liang, assistant professor and Dalton researcher and Sheng-You Huang, research associate.

"This is a good example of interdisciplinary research, where colleagues with different expertise collaborated to find targets and verify their use for breast cancer therapy. We couldn't have achieved this finding with each of us working on our own," Hyder said.


'/>"/>

Contact: Steven Adams
AdamsST@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert

Related medicine news :

1. Red wine compound increases anti-tumor effect of rapamycin
2. Scripps Research compound blocks brain cell destruction in Parkinsons disease
3. Bioactive compounds in berries can reduce high blood pressure
4. Finnish researchers find a compound that prevents the growth of prostate cancer cells
5. Drug-like compound stops thyroid overstimulation in early NIH studies
6. Compound that blocks sugar pathway slows cancer cell growth
7. New compounds may treat both alcohol and cigarette addictions
8. Scientists turn a new leaf to discover a compound in daffodils that targets brain cancer
9. OHSU research suggests compound administered during some bone marrow transplants elevates risks
10. New investigational compound targets pancreatic cancer cells
11. Compounds in non-stick cookware may be associated with elevated cholesterol in children and teens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program ... to announce the launch of the GFCP Scoop in response to ... purpose of the GFCP Scoop site is to keep the gluten-free ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... Cosmetic dentistry is a fast-growing field as more patients are discovering the many different ... more about the options currently available to them and which ones might work for ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Reltok Nasal Products ... products for the head and neck/ear, nose and throat specialty, has added the KOTLER ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by nasal ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, ... round of funding led by Eastside Partners, with participation from existing investor Martin ... customer base and accelerate its technology and product roadmap. , “Jvion ...
(Date:4/29/2016)... ... 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of ... them second place for Tampa’s Best Places to Work. They were ranked in the ... great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We work ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016   Click here ... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... a definitive agreement to acquire Valley Campus Pharmacy, ... ("TNH"), a leading specialty pharmacy that provides individualized ... California . In 2015, TNH generated approximately ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology: